KYORIN and Novartis Sign a $832.5M Global License Agreement for KRP-M223

Shots: KYORIN and Novartis entered into a global license agreement for KRP-M223 and its back-up compounds discovered by KYORIN As per the agreement, Novartis gets an exclusive global license to develop, manufacture, and commercialize KRP-M223, where KYORIN retains an option to commercialize and manufacture product for the Japanese market, with Novartis retaining an option to co-promote…

ByRidhi RastogiMarch 4, 2025

NEWS

Novartis to Acquire Anthos Therapeutics for ~$3.1B

Shots: Novartis to acquire Anthos (launched by Blackstone Life Sciences & Novartis in 2019) for ~$3.1B to boosts its cardiovascular portfolio with Anthos’ abelacimab; closing expected in H1’25 As per the deal, Anthos will receive $925M upfront & is eligible to receive ~$2.15B in regulatory & commercial milestones Abelacimab (licensed from Novartis) showed…

ByRidhi RastogiFebruary 11, 2025

NEWS

Dawn Health & Novartis Introduce Cora BC to Support Breast Cancer Patients

Shots: Dawn Health & Novartis have launched Cora BC app to offer support to all breast cancer pts & their kin following the development of Ekiva MS & Ekiva PNH. Launch will start in Germany, extending to other markets incl. UK, Canada & Australia Cora BC tracks pts health with regular check-ins, intuitive graphs, plus personalized reminders…

ByadminFebruary 5, 2025

INSIGHTS+

Key Takeaways of J.P. Morgan Healthcare Conference 2025

Shots: The 43rd Annual J.P. Morgan Conference took place from 13th to 16th January in San Francisco, USA. J.P. Morgan Healthcare Conference serves as a pioneering hub that features presentations and dialogues on the advances of the healthcare industry by bringing healthcare professionals, researchers, manufacturers, and other healthcare stakeholders to one platform. Innovation remained the…

ByHimanshu SehgalJanuary 28, 2025

NEWS

Light Horse Therapeutics Partners with Novartis to Discover Therapies for Cancer Treatment

Shots: Light Horse has entered into a multi-target partnership with Novartis to discover & develop FIC targets for cancer treatment by using its proprietary chemical libraries & precision genetic editing platform that identifies novel functional domains in disease-critical targets As per the agreement, Light Horse is entitled to receive $25M upfront, $1B research, development…

BySenior EditorJanuary 10, 2025

TOP 20

Top 20 Immunology Companies of 2024

Shots: Immunology remains one of the most explored therapy areas. Companies focusing on immunology are steadfastly working to advance treatment options by developing drugs, vaccines, and antibodies In 2023, the global immunology market size was valued at $98.22B and expected to register $263.22B by 2033, with a CAGR of 10.36% from 2024 to 2033. AbbVie…

ByPrince GiriJuly 25, 2024

INSIGHTS+

PharmaShots’ Key Highlights of Second Quarter 2024

Shots: The second quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Vertex’ acquisition of Alpine Immune Sciences for ~$4.9B This quarter also showcased multiple clinical trial results including Moderna’s P-III Study Data of mRNA-1283 Vaccine to Prevent COVID-19…

BySenior EditorJuly 2, 2024

INSIGHTS+

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2004-2023)

Shots: Witness the journey of the biopharma companies over 20 years with this informative and engaging report. The report highlights the development of the biopharma industry and the key factors influencing them In 2023, JNJ reclaims the topmost position in the list from Pfizer with a revenue of $85.16B, showcasing a sharp 10.30 percent vs…

BySaurabh ChaubeyMay 1, 2024

TOP 20

Top 20 RNAi Therapeutic Companies of 2024

Shots: RNAi therapeutics are innovative medications that enable rapid identification of specific inhibitors of disease targets across a wide range of molecule classes. Several biopharma companies are investing in RNAi therapeutics extravagantly to maintain a healthy foothold in innovative medicines In 2023, the global RNAi drug delivery market size was valued at $84.1B and is…

ByPrince GiriApril 25, 2024

INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2024

Shots: The first quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Gilead's acquisition of CymaBay Therapeutics for an aggregate of ~$4.3B This quarter also showcased multiple clinical trial results including Axsome Therapeutics P-III results for AXS-12 and BMS'…

BySenior EditorApril 1, 2024

KYORIN and Novartis Sign a $832.5M Global License Agreement for KRP-M223

Novartis to Acquire Anthos Therapeutics for ~$3.1B

Dawn Health & Novartis Introduce Cora BC to Support Breast Cancer Patients

Key Takeaways of J.P. Morgan Healthcare Conference 2025

Light Horse Therapeutics Partners with Novartis to Discover Therapies for Cancer Treatment

Top 20 Immunology Companies of 2024

PharmaShots’ Key Highlights of Second Quarter 2024

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2004-2023)

Top 20 RNAi Therapeutic Companies of 2024

PharmaShots’ Key Highlights of First Quarter 2024

Contact US

OUR INFORMATION

FOLLOW US